Core Viewpoint - Stellus Capital Investment Corporation is set to release its financial results for Q1 2025 on May 12, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results for the first quarter ended March 31, 2025, will be disclosed on May 12, 2025 [1] - A conference call to discuss these results will take place on May 13, 2025, at 10:00 AM Central Time, which is a change from the previously scheduled time [2] Group 2: Conference Call Details - The conference call can be accessed via phone by dialing 888-506-0062 with passcode 260621 [3] - A replay of the conference call will be available starting approximately two hours after the call until May 27, 2025, by dialing 877-481-4010 and entering passcode 52407 [3] - The conference will also be available via live webcast on the company's website, with a replay accessible for approximately 90 days [3] Group 3: Company Overview - Stellus Capital Investment Corporation is an externally-managed, closed-end, non-diversified investment management company regulated as a business development company under the Investment Company Act of 1940 [4] - The company's investment objective is to maximize total return to stockholders through current income and capital appreciation by investing primarily in private middle-market companies with EBITDA between $5.0 million and $50.0 million [4] - Investment activities are managed by Stellus Capital Management, LLC [4]

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company responsible for providing management services to CompoSecure Holdings, L.L.C. (“CompoSecure Holdings”), a wholly owned subsidiary of CompoSecure, Inc. (“CompoSecure”) (Nasdaq: CMPO), today reported financial results for its fiscal first quarter ending March 31, 2025. Resolute Holdings reported first quarter earnings per share attributable to common stockholders ...

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives t ...

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Expect to progress M4 positive allosteric modulator (PAM) program into the clinic in mid-2025 Secured $125 million venture debt facility from K2 HealthVentures, with $40 million available in 2025; cash runw ...

Core Viewpoint - American Shared Hospital Services (AMS) is set to discuss its first quarter 2025 financial results in a conference call scheduled for May 15, 2025, at 12:00 pm ET [1]. Financial Results Announcement - The financial results press release for the first quarter of 2025 will be issued before the market opens on May 15, 2025 [2]. Teleconference and Webcast Information - Domestic callers can join the call by dialing 1-844-413-3972, while international callers can dial 1-412-317-5776, at least 10 minutes prior to the start [3] - A simultaneous webcast will be available on the company's website [3] - A replay of the call will be accessible until May 22, 2025, through specified phone numbers and the company's website [3] Company Overview - AMS is a leading provider of turnkey solutions for cancer treatment centers, health systems, and cancer networks in North and South America [4] - The company collaborates with partners to enhance cancer service lines and provide integrated care close to patients' homes [4] - AMS shares capital investment costs and profitability with health system partners based on ownership interests [4]

Core Insights - Quest Resource Holding Corporation reported first quarter financial results that were in line with expectations, reflecting temporary cost increases and not yet the impact of performance-focused initiatives [4][6] - The company completed the sale of a non-core business segment for $5 million, which was utilized to pay down debt, and anticipates annual savings of $3 million from cost reductions and headcount decreases [1][6] - The company is focused on enhancing its performance culture, implementing short-term initiatives, and developing long-term efficiency programs to improve financial performance [4][5] Financial Performance - Revenue for the first quarter of 2025 was $68.4 million, a decrease of 5.8% compared to the same period in 2024 [6] - Gross profit was $10.9 million, down 22.1% year-over-year, resulting in a gross margin of 16.0%, compared to 19.3% in the first quarter of 2024 [6] - The GAAP net loss per share was $(0.50), compared to $(0.03) in the first quarter of 2024, with an adjusted net loss per diluted share of $(0.14) compared to adjusted net income of $0.08 in the prior year [6][15] Operational Highlights - The company recognized a non-cash loss on the sale of assets of $4.4 million and an impairment charge of $1.7 million on intangible assets [6] - Adjusted EBITDA for the first quarter was $1.6 million, down from $5.1 million in the same quarter of 2024 [6][14] - The company has amended agreements with existing lenders to enhance financial flexibility [1][6] Strategic Initiatives - Quest is committed to generating cash, increasing profitability, and reducing debt, with ongoing efforts to onboard blue-chip clients and improve operational efficiencies [4][5] - The company has initiated short-term initiatives and is developing long-term efficiency programs aimed at increasing earnings and cash generation [6][5] - A new CEO and Senior VP of Operations have been appointed, both with extensive industry experience focused on enhancing operational performance [6]

Company Announcement - Shimmick Corporation will release its first quarter 2025 financial results after market close on May 14, 2025 [1] - A video webcast conference call to discuss the results will be held at 5:00 p.m. Eastern Time on the same day [2] Company Overview - Shimmick is a leading infrastructure solutions provider specializing in complex projects related to water, climate resilience, energy transition, and sustainable transportation [3] - The company integrates technical excellence with collaborative project delivery methods to provide innovative, technology-driven infrastructure solutions [3] - Shimmick has a track record spanning over a century and is headquartered in California [3]

Company Overview - C3is Inc. is a ship-owning company that provides seaborne transportation services to dry bulk and tanker charterers, including major national and private industrial users, commodity producers, and traders [3] - As of the end of Q1 2025, the company owns three Handysize dry bulk carriers and one Aframax oil tanker, with a total capacity of 213,464 deadweight tons (dwt) [3] - The company's shares are listed on the Nasdaq Capital Market under the symbol "CISS" [3] Upcoming Financial Results - C3is Inc. will release its first quarter financial results for the period ended March 31, 2025, before the market opens in New York on May 15, 2025 [1] - A conference call will be hosted by the company's management on May 15, 2025, at 10:00 am ET to present the results and discuss the company's operations and outlook [1] - There will be a live and archived webcast of the conference call available on the C3is Inc. website [2]

Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ETPORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Compan ...

Core Viewpoint - NeurAxis, Inc. reported strong financial growth in Q1 2025, with a 39% year-over-year revenue increase, driven by expanding treatment access and positive payer coverage for its neuromodulation therapies [4][7]. Financial Highlights - Revenues for Q1 2025 reached $896 thousand, up from $647 thousand in Q1 2024, marking a 39% increase year-over-year and an 18% increase quarter-over-quarter [7][9]. - Operating loss improved by 9% when excluding a one-time legal settlement, with a reported operating loss of $2.3 million, an increase of 25% compared to $1.8 million in Q1 2024 [12][13]. - Cash balance as of March 31, 2025, was $2.0 million, with no long-term debt [14]. Operational Highlights - The company treated 300 patients in Q1 2025, indicating an annualized treatment rate of 1,200 patients, which is still a small fraction of the 600,000 children in the U.S. suffering from IBS [4][6]. - Positive coverage policies now encompass approximately 51 million lives, a significant increase from 4 million as of December 31, 2023 [5][7]. - NeurAxis received FDA clearance for expanding the IB-Stim label to include patients aged 8-21 and for its rectal expulsion device (RED), which is expected to generate meaningful revenues starting in Q2 2025 [7][8]. Management Commentary - The CEO highlighted that the growth is attributed to physicians becoming more comfortable with billing processes and increased awareness of treatment guidelines [5][6]. - The company anticipates that the upcoming publication of academic society guidelines and the implementation of a Category I CPT code on January 1, 2026, will be critical for expanding insurance coverage and driving national growth [6][9]. Market Position - NeurAxis is focused on expanding its pediatric addressable market and has submitted for FDA clearance to include pediatric Functional Dyspepsia, which could effectively double its market size [8]. - The company is committed to clinical research, with 16 peer-reviewed publications supporting its PENFS technology, enhancing its position for expanding payer coverage [7].